Compass Pathways said Tuesday that patients in the second of its two pivotal psilocybin trials maintained their response to treatment for at least six months, keeping the company on track to complete its NDA filing …
Source: Endpoints News
You may also like
Macrophage Membrane-Derived Nanoparticles Shows...
Stem Cell Therapy Shows Promise in First Human...
Ag Genomics Begins to Bear Fruit
StockWatch: Insilico Projects Profit, Revenue Leaps as...
[Podcast] From Protocol to Patient: Inside Clinical...
KKR-backed Allyntra debuts to serve medtech industry...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.